Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

Abstract

We have analysed 20 out of 245 patients with newly diagnosed chronic phase CML that had a still palpable spleen at 3rd month of imatinib therapy in terms of treatment response at 18 months from the start of treatment. 8 (40%) patients had achieved treatment response at these time point. Slower spleen shrinkage in patients with newly diagnosed chronic phase CML does not necessarily mean the failure of the therapy. 10.1002/ajh.21689

Keywords

• splenomegaly
• imatinib therapy
• chronic myelogenous leukemia